504 related articles for article (PubMed ID: 19283693)
21. Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope.
Li J; Chen X; Jiang S; Chen YH
Biochem Biophys Res Commun; 2008 Nov; 376(1):60-4. PubMed ID: 18762167
[TBL] [Abstract][Full Text] [Related]
22. Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions.
Dennison SM; Stewart SM; Stempel KC; Liao HX; Haynes BF; Alam SM
J Virol; 2009 Oct; 83(19):10211-23. PubMed ID: 19640992
[TBL] [Abstract][Full Text] [Related]
23. The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.
Huarte N; Lorizate M; Maeso R; Kunert R; Arranz R; Valpuesta JM; Nieva JL
J Virol; 2008 Sep; 82(18):8986-96. PubMed ID: 18596094
[TBL] [Abstract][Full Text] [Related]
24. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies.
Yang G; Holl TM; Liu Y; Li Y; Lu X; Nicely NI; Kepler TB; Alam SM; Liao HX; Cain DW; Spicer L; VandeBerg JL; Haynes BF; Kelsoe G
J Exp Med; 2013 Feb; 210(2):241-56. PubMed ID: 23359068
[TBL] [Abstract][Full Text] [Related]
25. Structural constraints imposed by the conserved fusion peptide on the HIV-1 gp41 epitope recognized by the broadly neutralizing antibody 2F5.
de la Arada I; Julien JP; de la Torre BG; Huarte N; Andreu D; Pai EF; Arrondo JL; Nieva JL
J Phys Chem B; 2009 Oct; 113(41):13626-37. PubMed ID: 19754136
[TBL] [Abstract][Full Text] [Related]
26. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.
Stiegler G; Kunert R; Purtscher M; Wolbank S; Voglauer R; Steindl F; Katinger H
AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1757-65. PubMed ID: 11788027
[TBL] [Abstract][Full Text] [Related]
27. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes.
Matyas GR; Wieczorek L; Beck Z; Ochsenbauer-Jambor C; Kappes JC; Michael NL; Polonis VR; Alving CR
AIDS; 2009 Oct; 23(16):2069-77. PubMed ID: 19710597
[TBL] [Abstract][Full Text] [Related]
28. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.
Guenaga J; Wyatt RT
PLoS Pathog; 2012; 8(7):e1002806. PubMed ID: 22829767
[TBL] [Abstract][Full Text] [Related]
29. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints.
Tian Y; Ramesh CV; Ma X; Naqvi S; Patel T; Cenizal T; Tiscione M; Diaz K; Crea T; Arnold E; Arnold GF; Taylor JW
J Pept Res; 2002 Jun; 59(6):264-76. PubMed ID: 12010517
[TBL] [Abstract][Full Text] [Related]
30. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution.
Shen X; Dennison SM; Liu P; Gao F; Jaeger F; Montefiori DC; Verkoczy L; Haynes BF; Alam SM; Tomaras GD
Proc Natl Acad Sci U S A; 2010 Mar; 107(13):5972-7. PubMed ID: 20231447
[TBL] [Abstract][Full Text] [Related]
31. Progress towards the development of a HIV-1 gp41-directed vaccine.
McGaughey GB; Barbato G; Bianchi E; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller MD; Pessi A; Shiver JW; Bogusky MJ
Curr HIV Res; 2004 Apr; 2(2):193-204. PubMed ID: 15078183
[TBL] [Abstract][Full Text] [Related]
32. The neutralizing epitope ELDKWA on HIV-1 gp41: genetic variability and antigenicity.
Dong XN; Wu Y; Chen YH
Immunol Lett; 2005 Oct; 101(1):81-6. PubMed ID: 15951025
[TBL] [Abstract][Full Text] [Related]
33. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.
Brunel FM; Zwick MB; Cardoso RM; Nelson JD; Wilson IA; Burton DR; Dawson PE
J Virol; 2006 Feb; 80(4):1680-7. PubMed ID: 16439525
[TBL] [Abstract][Full Text] [Related]
34. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
Ofek G; Tang M; Sambor A; Katinger H; Mascola JR; Wyatt R; Kwong PD
J Virol; 2004 Oct; 78(19):10724-37. PubMed ID: 15367639
[TBL] [Abstract][Full Text] [Related]
35. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.
Li D; Liu J; Zhang L; Xu T; Chen J; Wang L; Zhao Q
Virol Sin; 2015 Dec; 30(6):449-56. PubMed ID: 26715302
[TBL] [Abstract][Full Text] [Related]
36. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.
Chen Y; Zhang J; Hwang KK; Bouton-Verville H; Xia SM; Newman A; Ouyang YB; Haynes BF; Verkoczy L
J Immunol; 2013 Aug; 191(3):1260-75. PubMed ID: 23825311
[TBL] [Abstract][Full Text] [Related]
37. [Immunogenetic properties of peptides mimicking a human immunodeficiency virus gp41 (HIV-1) epitope recognized by virus-neutralizing antibody 2F5].
Tumanova OIu; Kuvshinov VN; Orlovskaia IA; Proniaeva TR; Pokrovskiĭ AG; Il'ichev AA; Sandakhchiev LS
Mol Biol (Mosk); 2003; 37(3):556-60. PubMed ID: 12815965
[TBL] [Abstract][Full Text] [Related]
38. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.
Luo M; Yuan F; Liu Y; Jiang S; Song X; Jiang P; Yin X; Ding M; Deng H
Vaccine; 2006 Jan; 24(4):435-42. PubMed ID: 16143433
[TBL] [Abstract][Full Text] [Related]
39. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions.
Neurath AR; Strick N; Lin K; Jiang S
AIDS Res Hum Retroviruses; 1995 Jun; 11(6):687-96. PubMed ID: 7576928
[TBL] [Abstract][Full Text] [Related]
40. Recognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicity.
Huarte N; Araujo A; Arranz R; Lorizate M; Quendler H; Kunert R; Valpuesta JM; Nieva JL
PLoS One; 2012; 7(12):e52740. PubMed ID: 23285173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
